Modality
Multispecific
MOA
BCL-2i
Target
FLT3
Pathway
mTOR
CMLMigraineMS
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
Feb 2017
→ Jun 2029
Phase 2Current
NCT07035347
874 pts·MS
2017-02→2029-06·Terminated
874 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-079mo agoNDA· Migraine
2029-06-153.2y awayPh2 Data· MS
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Termina…
Catalysts
NDA
2025-07-07 · 9mo ago
Migraine
Ph2 Data
2029-06-15 · 3.2y away
MS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07035347 | Phase 2 | MS | Terminated | 874 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |